DE-CSC
17.11.2020 13:02:04 CET | Business Wire | Press release
CSC , a world leader in business, legal, tax, and domain security, today released new research from their Digital Brand Services (DBS) division warning consumers that simple URL typos could lead to significant online fraud, counterfeit goods, and cyber crime during the holiday shopping season. The company identified and analyzed registered domain typos (misspellings) associated with the 10 largest online shopping brands in the world and found that over 70% of the 1,553 registered domain typos appear to be owned by third parties.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201117005233/en/
According to CSC’s new research , these third-party owned domains receive over five million visitors annually. In addition, 40% of these domains are using domain privacy services to mask or hide their ownership and identity, and close to 48% are configured with MX (mail) records that can be used for phishing and to intercept email. In its blog, CSC offers tips to both brand owners and consumers to protect themselves against fraudulent web properties and content.
A deep dive of the top 100 most visited typo domains shows they are being used in this manner:
- 38% are pointing to advertising-related and pay-per-click web content, which can be used to spread malware via domain parking services
- 27% had no live web content, yet 37% were configured to send and receive email with MX records
- 15% were engaged in affiliate referrals, which means the brand owner could be targeted for unauthorized affiliate activity resulting in loss of revenue
- 12% were pointing at shopping-related web content, which indicates that consumers could engage with nefarious retailers selling counterfeit goods while brand owners lose revenue
- 8% were pointing toward malicious web content e.g., malware
During the holiday shopping season, just one hour of downtime can cost a business over $500,000 in lost revenue*. Despite this, many global eCommerce and shopping companies are still lacking basic domain security measures that could prevent this from happening. For instance, only 16% of the top 500 global eCommerce and shopping domains leverage domain name system (DNS) hosting redundancy, which could secure their online presence from a distributed denial of service (DDoS) attacks. In addition, only 18% use registry locks that prevent DNS hijacking attacks that could redirect consumers to alternate websites. Lastly, 40% of retailers do not use enterprise-class domain registrars. This is partially explained by the fact that 40% of the observed domains still rely on retail registrars that typically don’t provide advanced domain security features.
“ In light of the global pandemic, both consumers and leading brands have embraced online shopping as we head into the 2020 holiday season. As such, we wanted to call attention to how brands and consumers are at increased risk for a multitude of threat vectors associated with online fraud, counterfeits, revenue leakage and many other cyber criminal activities this year,” says Ihab Shraim, chief technology officer for CSC. “As evidenced by the sheer number of mail-in votes in the U.S. election, consumers are looking for safe alternatives to in-person interactions, and it’s important for brands to not only provide those digital channels, but also ensure they are secure from online threat vectors.”
“We’re delighted that companies like CSC are advocating for companies and online brands to put the necessary security protocols in place to protect not only their brand reputation, but their consumers, from online fraud and cyber crime,” says Daniel Eliot, director of Education and Strategic Initiatives at the National Cyber Security Alliance (NCSA). “The NCSA's mission is to educate consumers and businesses about these credible risks, and the importance of using recommended cyber security best practices. CSC’s research is also an important part of advocating for consumers, and showing the pervasive risk of these cyber attacks and fraudulent domains.”
Additional resources:
- Blog post
- Consumer tips infographic
*gremlin.com/ecommerce-cost-of-downtime/
About CSC
CSC is the trusted provider of choice for the Forbes Global 2000 and the 100 Best Global Brands® in enterprise domain names, domain name system, digital certificate management, as well as digital brand and fraud protection. As global companies make significant investments in their security posture, CSC can help them understand known security blind spots that exist and help them secure their digital assets. By leveraging CSC’s proprietary solutions, companies can get secure to protect against cyber threats to their online assets, helping them avoid devastating revenue loss, brand reputation damage, or significant financial penalties because of policies like the General Data Protection Regulation (GDPR). CSC also provides online brand protection—the combination of online brand monitoring and enforcement activities—taking a holistic approach to digital asset protection, along with fraud protection services to combat phishing. Headquartered in Wilmington, Delaware, USA, since 1899, CSC has offices throughout the United States, Canada, Europe, and the Asia-Pacific region. CSC is a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. Visit cscdbs.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201117005233/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
